AI-Enabled Microfluidics for Respiratory Pathogen Detection

Respiratory infectious diseases, such as COVID-19, influenza, and tuberculosis, continue to impose a significant global health burden, underscoring the urgent demand for rapid, sensitive, and cost-effective diagnostic technologies. Integrated microfluidic platforms offer compelling advantages through miniaturization, automation, and high-throughput processing, enabling “sample-in, answer-out” workflows suitable for point-of-care applications. However, their clinical deployment faces challenges, including the complexity of sample matrices, low-abundance target detection, and the need for reliable multiplexing. The convergence of artificial intelligence (AI) with microfluidic systems has emerged as a transformative paradigm, addressing these limitations by optimizing chip design, automating sample pre-processing, enhancing signal interpretation, and enabling real-time feedback control. This critical review surveys AI-enabled strategies across each functional layer of respiratory pathogen diagnostics: from chip architecture and fluidic control to amplification analysis, signal prediction, and smartphone/IoT-linked decision support. We highlight key areas where AI offers measurable benefits over conventional methods. To transition from research prototypes to clinical tools, future systems must become more adaptive, data-efficient, and clinically insightful. Advances such as sensor-integrated chips, privacy-preserving machine learning, and multimodal data fusion will be essential to ensure robust performance and meaningful outputs across diverse scenarios. This review outlines recent progress, current limitations, and future directions. The rapid development of AI and microfluidics presents exciting opportunities for next-generation pathogen diagnostics, and we hope this work contributes to the advancement of intelligent, point-of-care testing (POCT) solutions.